Jean-Pierre Routy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jean-Pierre Routy has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
C. Tremblay
Centre de Recherche du Centre Hospitalier de l'Universite de Montreal
2 shared publicationsCharles Nicolette
Argos Therapeutics Inc, Durham, NC, USA
2 shared publicationsDanielle Rouleau
From the aImmunodeficiency Service and Division of Hematology, McGill University Health Centre, McGill University, bClinique médicale l'Actuel, cDivision of Clinical Epidemiology, McGill University, dMcGill AIDS Centre, McGill University, eCentre Hospitalier de l'Université de Montréal, Université de Montréal, fClinique médicale du Quartier Latin, Montreal, Quebec, and gDepartment of Public Health Sciences, University of Toronto, Toronto, Ontario, Canada
2 shared publicationsPierre Côté
From the aImmunodeficiency Service and Division of Hematology, McGill University Health Centre, McGill University, bClinique médicale l'Actuel, cDivision of Clinical Epidemiology, McGill University, dMcGill AIDS Centre, McGill University, eCentre Hospitalier de l'Université de Montréal, Université de Montréal, fClinique médicale du Quartier Latin, Montreal, Quebec, and gDepartment of Public Health Sciences, University of Toronto, Toronto, Ontario, Canada
2 shared publicationsAlain Bestawros
Division of Internal Medicine, Montreal General Hospital and McGill University, Montreal, Canada
1 shared publicationB. Yassine-Diab
Centre de Recherche du Centre Hospitalier de l'Universite de Montreal
1 shared publication
Latest Publications
- Open Access
- 16 June 2011
- Published by Springer Nature in AIDS Research and Therapy
- Vol. 8 (1) , 20
T cell Activation does not drive CD4 decline in longitudinally followed HIV-infected Elite Controllers
Elite controllers (EC) are a rare subset of HIV infected individuals who control viral load below 50 copies/ml of plasma without treatment. Thirty four EC were studied. The slope of CD4 count change was available for 25 of these subjects. We assessed immune activation by measuring the percent of CD38+HLA-DR+CD8+ T cells in the EC group and comparing it with that in 24 treatment-naïve HIV disease progressors and 13 HIV uninfected healthy controls. Compared to HIV uninfected subjects, EC had higher percentages of CD38+HLA-DR+CD8+ T cells (p < 0.001) that was lower than that observed in progressors (p < 0.01). Fifteen of 25 EC had a slope of CD4 count change that was not significantly different from 0 while 3 had a positive and 7 a negative CD4 count slope. Immune activation did not distinguish EC subsets with stable/increasing versus declining CD4 counts. Elevated immune activation in ECs is not associated with a faster rate of CD4 decline
- 16 June 2011
- Published by Springer Nature in AIDS Research and Therapy
- Vol. 8 (1) , 20
Open AccessT cell Activation does not drive CD4 decline in longitudinally followed HIV-infected Elite Controllers
Elite controllers (EC) are a rare subset of HIV infected individuals who control viral load below 50 copies/ml of plasma without treatment. Thirty four EC were studied. The slope of CD4 count change was available for 25 of these subjects. We assessed immune activation by measuring the percent of CD38+HLA-DR+CD8+ T cells in the EC group and comparing it with that in 24 treatment-naïve HIV disease progressors and 13 HIV uninfected healthy controls. Compared to HIV uninfected subjects, EC had higher percentages of CD38+HLA-DR+CD8+ T cells (p < 0.001) that was lower than that observed in progressors (p < 0.01). Fifteen of 25 EC had a slope of CD4 count change that was not significantly different from 0 while 3 had a positive and 7 a negative CD4 count slope. Immune activation did not distinguish EC subsets with stable/increasing versus declining CD4 counts. Elevated immune activation in ECs is not associated with a faster rate of CD4 decline
- 16 July 2010
- Published by Taylor & Francis in Immunotherapy
- Vol. 2 (4) , 467-476
Arcelis™ AGS-004 dendritic cell-based immunotherapy for HIV infection
Antiretroviral therapy represents a major breakthrough for the management of HIV-infected patients; however, it is not without side effects and is a life-long commitment. Thus, the development of novel strategies to enhance immune response and control viral replication are needed in order to limit exposure to antiretroviral therapy. To date, immunotherapies consisting of monocyte-derived dendritic cells expressing HIV antigens have elicited only limited immunogenicity and/or viral control. Thus, taking into consideration the variability of HIV, an investigational immunotherapeutic product (AGS-004, Argos Therapeutics Inc., NC, USA) that consists of autologous dendritic cells co-electroporated with in vitro transcribed RNA encoding four of the patient's own HIV antigens was developed. Based on the encouraging immunogenicity and tolerance observed in a Phase I study, a Phase II study has been initiated with good tolerance and partial viral control. A second Phase II placebo-controlled study is about to initiate.
- 16 July 2010
- Published by Taylor & Francis in Immunotherapy
- Vol. 2 (4) , 467-476
Arcelis™ AGS-004 dendritic cell-based immunotherapy for HIV infection
Antiretroviral therapy represents a major breakthrough for the management of HIV-infected patients; however, it is not without side effects and is a life-long commitment. Thus, the development of novel strategies to enhance immune response and control viral replication are needed in order to limit exposure to antiretroviral therapy. To date, immunotherapies consisting of monocyte-derived dendritic cells expressing HIV antigens have elicited only limited immunogenicity and/or viral control. Thus, taking into consideration the variability of HIV, an investigational immunotherapeutic product (AGS-004, Argos Therapeutics Inc., NC, USA) that consists of autologous dendritic cells co-electroporated with in vitro transcribed RNA encoding four of the patient's own HIV antigens was developed. Based on the encouraging immunogenicity and tolerance observed in a Phase I study, a Phase II study has been initiated with good tolerance and partial viral control. A second Phase II placebo-controlled study is about to initiate.
- 1 February 2010
- Published by Elsevier in Clinical Immunology
- Vol. 134 (2) , 140-147
Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapy
- 1 February 2010
- Published by Elsevier in Clinical Immunology
- Vol. 134 (2) , 140-147
Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapy
- Open Access
- 16 February 2008
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 152 (1) , 72-80
Persistent human immunodeficiency virus-1 antigenaemia affects the expression of interleukin-7Rα on central and effector memory CD4+ and CD8+ T cell subsets
Interleukin (IL)-7 and its receptor (IL-7Rα) play important roles in regulating lymphopoiesis. Previous studies have reported that human immunodeficiency virus-1 (HIV-1) viraemia affects the expression of IL-7Rα, but its effects on CD4+ and CD8+ T cell memory subsets have not been studied. Using eight-colour flow cytometry, we compared the immunophenotypic patterns of CD4+ and CD8+ T cell subsets expressing IL-7Rα and activation markers, as well as circulating IL-7 levels, in three well-defined groups of HIV-1-infected subjects: successfully treated, viraemic and long-term non-progressor (LTNP). Compared with successfully treated and LTNP subjects, viraemic patients had reduced expression of IL-7Rα on both CD4+ and CD8+ T cells, particularly on central and effector memory T cell compartments, and substantially elevated expression of activation markers on CD8+ T cell subsets. Circulating IL-7 levels were correlated negatively with the number of CD4+ and CD8+ T cell subsets expressing IL-7Rα; these associations were stronger with CD4+ T cell subsets and mainly with central and effector memory cells. The expression of activation markers on CD4+ and CD8+ cell T subsets was not related to circulating IL-7 levels. A strong negative correlation was observed between central memory CD4+ or CD8+ T cells expressing IL-7Rα and those expressing activation markers, independently of IL-7 levels. Collectively, these results provide further insight on the role of unsuppressed viral load in disrupting the IL-7/IL-7Rα system and contributing to HIV-1 disease progression.
- 16 February 2008
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 152 (1) , 72-80
Open AccessPersistent human immunodeficiency virus-1 antigenaemia affects the expression of interleukin-7Rα on central and effector memory CD4+ and CD8+ T cell subsets
Interleukin (IL)-7 and its receptor (IL-7Rα) play important roles in regulating lymphopoiesis. Previous studies have reported that human immunodeficiency virus-1 (HIV-1) viraemia affects the expression of IL-7Rα, but its effects on CD4+ and CD8+ T cell memory subsets have not been studied. Using eight-colour flow cytometry, we compared the immunophenotypic patterns of CD4+ and CD8+ T cell subsets expressing IL-7Rα and activation markers, as well as circulating IL-7 levels, in three well-defined groups of HIV-1-infected subjects: successfully treated, viraemic and long-term non-progressor (LTNP). Compared with successfully treated and LTNP subjects, viraemic patients had reduced expression of IL-7Rα on both CD4+ and CD8+ T cells, particularly on central and effector memory T cell compartments, and substantially elevated expression of activation markers on CD8+ T cell subsets. Circulating IL-7 levels were correlated negatively with the number of CD4+ and CD8+ T cell subsets expressing IL-7Rα; these associations were stronger with CD4+ T cell subsets and mainly with central and effector memory cells. The expression of activation markers on CD4+ and CD8+ cell T subsets was not related to circulating IL-7 levels. A strong negative correlation was observed between central memory CD4+ or CD8+ T cells expressing IL-7Rα and those expressing activation markers, independently of IL-7 levels. Collectively, these results provide further insight on the role of unsuppressed viral load in disrupting the IL-7/IL-7Rα system and contributing to HIV-1 disease progression.
- 20 November 2007
- Published by Wiley in American Journal of Hematology
- Vol. 83 (6) , 508-511
Multicentric Castleman's disease treated with combination chemotherapy and rituximab in four HIV‐positive men: A case series
Multicentric Castleman's disease (MDC) is a rare herpesvirus‐8‐related prelymphomatous condition that may develop in patients infected with human immunodeficiency virus (HIV). Therapy for MCD is not well established and most often includes: corticosteroids, single or combined chemotherapy, anti‐CD20 monoclonal antibody and antiretroviral therapy. In order to obtain a rapid and long‐lasting clinical response, we are reporting on a short course of anthracycline‐based chemotherapy associated with rituximab in HIV‐positive patients with MCD. Our study suggests that the combined immuno‐chemotherapy approach may represent a valid strategy with acceptable toxicity in patients with severe and extensive MDC. Further studies will be needed to assess the efficacy and safety of such an approach, and to identify risk factors predictive of long‐term tolerance in HIV patients with different degrees of immunosuppression. Am. J. Hematol., 2008.
- 20 November 2007
- Published by Wiley in American Journal of Hematology
- Vol. 83 (6) , 508-511
Multicentric Castleman's disease treated with combination chemotherapy and rituximab in four HIV‐positive men: A case series
Multicentric Castleman's disease (MDC) is a rare herpesvirus‐8‐related prelymphomatous condition that may develop in patients infected with human immunodeficiency virus (HIV). Therapy for MCD is not well established and most often includes: corticosteroids, single or combined chemotherapy, anti‐CD20 monoclonal antibody and antiretroviral therapy. In order to obtain a rapid and long‐lasting clinical response, we are reporting on a short course of anthracycline‐based chemotherapy associated with rituximab in HIV‐positive patients with MCD. Our study suggests that the combined immuno‐chemotherapy approach may represent a valid strategy with acceptable toxicity in patients with severe and extensive MDC. Further studies will be needed to assess the efficacy and safety of such an approach, and to identify risk factors predictive of long‐term tolerance in HIV patients with different degrees of immunosuppression. Am. J. Hematol., 2008.
- 1 August 2005
- Published by Elsevier in The Lancet
- Vol. 366 (9485) , 523-524
Valproic acid: a potential role in treating latent HIV infection
- 1 August 2005
- Published by Elsevier in The Lancet
- Vol. 366 (9485) , 523-524
Valproic acid: a potential role in treating latent HIV infection
- 1 November 2004
- Published by Wolters Kluwer Health in AIDS
- Vol. 18 (17) , 2305-2312
Factors associated with a decrease in the prevalence of drug resistance in newly HIV-1 infected individuals in Montreal
Objective: A decrease in the prevalence of drug resistance (DR) has been observed among recently infected (RI) individuals in Montreal. A study of chronically infected (CI) patients, who represent potential HIV-1 transmitters, was carried out in order to ascertain biological factors associated with this trend change. Design and methods: Retrospective analysis of CI patients was performed for the period 1996–2003. Changes in mean viral load and DR prevalence were assessed in CI patients (n = 2328) and compared to those in RI patients (n = 180) living in the same geographic area. Results: A decrease was observed in the prevalence of DR among RI patients, from 13.0% in 1997–2000 to 4.0% in 2001–2003 (P = 0.04). From 1996 to 2000, the mean viral load in the CI patients decreased by 1.34 log10, to remain steady thereafter. The proportion of CI patients who interrupt treatment increased steadily over 1997–2003 from 3.1% to 16.5% (P < 0.0001). Since 1999, when genotyping analysis became available, we have observed a 0.9 log10 decrease in mean viral load among 602 genotyped CI patients harbouring any major mutations. Conclusion: The decrease in transmission of DR documented in Montreal since 2000 coincides with the drop in mean viral load observed in CI patients. Factors that contribute to the decrease in viral load include routine access to genotyping and availability of more potent antiretroviral drugs. Plasma viral load seems to represent the main predictor for the transmission of DR.
- 1 November 2004
- Published by Wolters Kluwer Health in AIDS
- Vol. 18 (17) , 2305-2312
Factors associated with a decrease in the prevalence of drug resistance in newly HIV-1 infected individuals in Montreal
Objective: A decrease in the prevalence of drug resistance (DR) has been observed among recently infected (RI) individuals in Montreal. A study of chronically infected (CI) patients, who represent potential HIV-1 transmitters, was carried out in order to ascertain biological factors associated with this trend change. Design and methods: Retrospective analysis of CI patients was performed for the period 1996–2003. Changes in mean viral load and DR prevalence were assessed in CI patients (n = 2328) and compared to those in RI patients (n = 180) living in the same geographic area. Results: A decrease was observed in the prevalence of DR among RI patients, from 13.0% in 1997–2000 to 4.0% in 2001–2003 (P = 0.04). From 1996 to 2000, the mean viral load in the CI patients decreased by 1.34 log10, to remain steady thereafter. The proportion of CI patients who interrupt treatment increased steadily over 1997–2003 from 3.1% to 16.5% (P < 0.0001). Since 1999, when genotyping analysis became available, we have observed a 0.9 log10 decrease in mean viral load among 602 genotyped CI patients harbouring any major mutations. Conclusion: The decrease in transmission of DR documented in Montreal since 2000 coincides with the drop in mean viral load observed in CI patients. Factors that contribute to the decrease in viral load include routine access to genotyping and availability of more potent antiretroviral drugs. Plasma viral load seems to represent the main predictor for the transmission of DR.
- 1 January 2003
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 18 (2) , 55-60
Changes in immunological and virological parameters in HIV‐1 infected subjects following leukapheresis
In order to assess immune responses during HIV‐1 therapeutic immunization, a large number of blood mononuclear cells (PBMC) are needed. Clinical tolerance and safety, as well as changes in immunological and virological parameters, were assessed, following leukapheresis in HIV‐1 infected subjects with CD4+ cell count >200 × 106/l. PBMC were collected using a Fenwal CS3000 cell separator in 29 subjects with mean CD4+ cell counts of 503 × 106/l (range 172–1,119) and viral load of 2.5 log10 copies/ml (range 9/l lymphocytes was collected by a single apheresis in a mean volume of 200 ± 1.8 ml, containing 9.0 ± 1.3 × 109/l CD4+ and 10.2 ± 1.3 × 109/l CD8+ cells. The leukapheresis procedures were well tolerated and no immediate or delayed side effects were observed within 90 days of follow‐up. No changes from blood pre‐leukapheresis values were detected for white blood cells, lymphocytes, monocytes, CD8+, CD34+, naive and memory CD4+ cell counts immediately after, 1 h, 7 days, or within 90 days after leukapheresis. However, absolute CD4+ cell counts and percentage significantly increased from pre‐leukapheresis values after 1 h (530 ± 43 vs. 700 ± 75 cell × 106/l; 32.6 ± 1.6 vs. 36.9 ± 1.9%; P < 0.001 for both paired t‐tests) before returning to pre‐leukapheresis levels on day 7. No significant changes in viral load from pre‐leukapheresis levels in treated or untreated subjects were detected at any time points. We conclude that leukapheresis in HIV‐1 infected subjects with CD4+ cell counts >200 × 106/l is safe and induces a transient increase in the absolute and percentage of CD4+ cell count without enhancing viral replication. J. Clin. Apheresis 18:55–60, 2003.
- 1 January 2003
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 18 (2) , 55-60
Changes in immunological and virological parameters in HIV‐1 infected subjects following leukapheresis
In order to assess immune responses during HIV‐1 therapeutic immunization, a large number of blood mononuclear cells (PBMC) are needed. Clinical tolerance and safety, as well as changes in immunological and virological parameters, were assessed, following leukapheresis in HIV‐1 infected subjects with CD4+ cell count >200 × 106/l. PBMC were collected using a Fenwal CS3000 cell separator in 29 subjects with mean CD4+ cell counts of 503 × 106/l (range 172–1,119) and viral load of 2.5 log10 copies/ml (range 9/l lymphocytes was collected by a single apheresis in a mean volume of 200 ± 1.8 ml, containing 9.0 ± 1.3 × 109/l CD4+ and 10.2 ± 1.3 × 109/l CD8+ cells. The leukapheresis procedures were well tolerated and no immediate or delayed side effects were observed within 90 days of follow‐up. No changes from blood pre‐leukapheresis values were detected for white blood cells, lymphocytes, monocytes, CD8+, CD34+, naive and memory CD4+ cell counts immediately after, 1 h, 7 days, or within 90 days after leukapheresis. However, absolute CD4+ cell counts and percentage significantly increased from pre‐leukapheresis values after 1 h (530 ± 43 vs. 700 ± 75 cell × 106/l; 32.6 ± 1.6 vs. 36.9 ± 1.9%; P < 0.001 for both paired t‐tests) before returning to pre‐leukapheresis levels on day 7. No significant changes in viral load from pre‐leukapheresis levels in treated or untreated subjects were detected at any time points. We conclude that leukapheresis in HIV‐1 infected subjects with CD4+ cell counts >200 × 106/l is safe and induces a transient increase in the absolute and percentage of CD4+ cell count without enhancing viral replication. J. Clin. Apheresis 18:55–60, 2003.
- 1 August 2000
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 24 (5) , 425-432
Comparison of Clinical Features of Acute HIV-1 Infection in Patients Infected Sexually or Through Injection Drug Use
Acute HIV-1 infection (AHI) may present with a clinical picture that represents a diagnostic challenge. We tested the hypothesis that two different routes of infection, that is, sexual versus parenteral, might be associated with a difference in the clinical features of AHI. A prospective cohort of seroconvertors was established in Montréal in private medical clinics and hospitals from February 1996 to May 1999. The prevalence of the symptomatic presentation was almost overlapping within the two groups of newly infected individuals 69% (42 of 61) for men having sex with men (MSM) and 69% (18 of 26) for injection drug users (IDUs; p =.98). Comparison of all types of symptoms and signs as well as their duration was also similar in both groups. Of particular interest, the site of lymph node enlargement was not different despite the estimated sites of intravenous inoculation. Oral and anal ulcers were more frequently observed in MSM than in IDUs (6 versus 0 and 4 versus 1, respectively). Neither the mean CD4+ count (514.8 and 414.7 cells/mm3; p =.14) nor the mean viral load (4.45 and 4.70 log copies/ml; p =.40) were different between the two groups at the time of the first study visit. Our study results clearly indicate that health care workers can expect similar clinical presentation of AHI in MSM and in IDUs despite the different routes of infection.
- 1 August 2000
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 24 (5) , 425-432
Comparison of Clinical Features of Acute HIV-1 Infection in Patients Infected Sexually or Through Injection Drug Use
Acute HIV-1 infection (AHI) may present with a clinical picture that represents a diagnostic challenge. We tested the hypothesis that two different routes of infection, that is, sexual versus parenteral, might be associated with a difference in the clinical features of AHI. A prospective cohort of seroconvertors was established in Montréal in private medical clinics and hospitals from February 1996 to May 1999. The prevalence of the symptomatic presentation was almost overlapping within the two groups of newly infected individuals 69% (42 of 61) for men having sex with men (MSM) and 69% (18 of 26) for injection drug users (IDUs; p =.98). Comparison of all types of symptoms and signs as well as their duration was also similar in both groups. Of particular interest, the site of lymph node enlargement was not different despite the estimated sites of intravenous inoculation. Oral and anal ulcers were more frequently observed in MSM than in IDUs (6 versus 0 and 4 versus 1, respectively). Neither the mean CD4+ count (514.8 and 414.7 cells/mm3; p =.14) nor the mean viral load (4.45 and 4.70 log copies/ml; p =.40) were different between the two groups at the time of the first study visit. Our study results clearly indicate that health care workers can expect similar clinical presentation of AHI in MSM and in IDUs despite the different routes of infection.
- 1 April 1994
- p. S95-7
Comparative analysis of the T cell receptor V beta repertoire in various lymphoid tissues from HIV-infected patients: evidence for an HIV-associated superantigen.
The search to identify HIV-associated molecules with superantigenic properties has focussed on demonstration of T cell receptor V beta subset-specific perturbations in HIV-infected patients. In this report, the V beta repertoire of two HIV patients was studied in lymph nodes, where HIV-1 replication is the most intense, and compared to the repertoire found in peripheral blood. Use of this fully MHC-compatible system has allowed identification of a small, partly overlapping set of V beta determinants which appear significantly perturbed in HIV-1 infection. These results are consistent with the presence of an HIV-associated superantigen.
- 1 April 1994
- p. S95-7
Comparative analysis of the T cell receptor V beta repertoire in various lymphoid tissues from HIV-infected patients: evidence for an HIV-associated superantigen.
The search to identify HIV-associated molecules with superantigenic properties has focussed on demonstration of T cell receptor V beta subset-specific perturbations in HIV-infected patients. In this report, the V beta repertoire of two HIV patients was studied in lymph nodes, where HIV-1 replication is the most intense, and compared to the repertoire found in peripheral blood. Use of this fully MHC-compatible system has allowed identification of a small, partly overlapping set of V beta determinants which appear significantly perturbed in HIV-1 infection. These results are consistent with the presence of an HIV-associated superantigen.